logo

On the morning of January 2, Dong-A Socio Group held 2020 New Year's kick-off meeting at the 7F auditorium of the headquarters building with many employees and executives, including President Han Jong-hyun of Dong-A Socio Holdings, Chairman Eom Dae-sig of Dong-A ST, and President Choi Ho-jin of Dong-A Pharm, in attendance.

On December 24, ST Pharm (President Kim Gyeong-jin) announced that the US FDA had approved the phase I IND (investigational new drug application) of STP1002, a new drug for the treatment of colorectal cancer, in the US.

On December 16, Dong-A Socio Holdings (President Han Jong-hyun) announced that the company and Meiji Seika Pharma (President Kobayashi Daikichiro) had launched the phase I clinical study of DMB-3115, a biosimilar of Stelara, in Europe.

On December 2, Dong-A Socio Holdings (President Han Jong-hyun) announced its acquisition of the ISO27001 certification, the international standard for information security management systems.

On November 29, Dong-A Socio Group announced that the group held a founding ceremony on the 7F auditorium of Yongdu-dong Headquarters in Dongdaemun-gu, Seoul to commemorate the 86th anniversary of its founding.

On November 28, ST Pharm (President Kim Gyeong-jin) announced the submission of an IND (investigational new drug application) application to the US FDA for the phase I clinical studies of STP1002, a new drug for colorectal cancer, in the US.

Dong-A Socio Group has consistently engaged in heartwarming sharing with underprivileged citizens throughout the cold winter season for the last fifteen years.

On November 25, Dong-A Socio Group announced that the company would be carrying out ‘Grow Together’, a group-wide love sharing campaign, in which all employees of the group would be required to participate to commemorate the company’s 87th anniversary.

On November 19, ST Pharm (President Kim Kyung-jin) announced that the company had attended the ‘TIDES: Oligonucleotide and Peptide Therapeutics 2019’ meeting held for 4 days from November 12th.